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The indoleamine 2,3-dioxygenase-(IDO-) mediated microenvironment plays an important role in tumor immune escape.
However, the inhibitory eﬀects of IDO on the CD8+ tumour-inﬁltrating lymphocytes (CD8+ TILs) in esophageal squamous
cell carcinoma (ESCC) have not been clariﬁed yet. Here, we found that the level of IDO expression in ESCC tumor specimens
correlated with a reduction in the number of CD8+ TILs. Patients with high IDO expression and a low number of CD8+ TILs had
signiﬁcantly impaired overall survival time. IDO expression and functional enzyme activity in ESCC cell lines could be induced
by IFNγ. When exposed to the milieu generated by IDO-expressing Eca109 cells, the CD8+ TILs were suppressed in proliferation,
and their cytolytic functions against target tumor cells were lost. These results suggested that impairing CD8+ TIL functions by
IDO expressed in ESCC possibly contributed to the ﬁnding that patients with higher IDO expression have more aggressive disease
p r o g r e s s i o na n ds h o r t e ro v e r a l ls u r v i v a lt i m e .
1.Introduction
Eﬀector CD8+ tumor-inﬁltrating lymphocytes (CD8+ TILs)
are major mediators for host’s antitumor immunity [1–5].
Increasing studies have reported that higher numbers of
CD8+ TILs within either esophageal squamous cell carci-
noma (ESCC) epithelium or stroma have a better prog-
nosis [6, 7]. Recently, several reports showed that tumoral
indoleamine 2,3-dioxygenase (IDO) expression correlated
with a reduced number of CD8+ or CD3+ TILs in colorectal
cancer, ovarian cancer, and endometrial cancer, possibly
contributing to disease progression and impaired clinical
outcome [8–10].
IDO is responsible for initiating the ﬁrst rate-limiting
step in tryptophan (Trp) metabolism in the kynurenine
(Kyn) pathway [11, 12]. Growing evidence suggests that
various types of human tumor cells express IDO, and
inﬂammatory mediators, especially interferon-γ (IFNγ),
have the speciﬁc ability to induce IDO expression [13, 14].
Tumoral IDO expression has been shown to correlate with
poor clinical prognosis in ovarian carcinoma, endometrial
carcinoma, lung cancer, osteosarcoma, and colon carcinoma
[8, 15–18]. IDO-mediated Trp metabolism in antigen-
presenting cells and tumor cells represents a vital mechanism
for potential T-cell suppression during tumor growth [19–
21]. In the experimental rat lung allograft model, IDO not
only reduced the number of CD8+ T cell inﬁltration but
alsoimpairedthecytotoxicfunctionofeﬀectorCD8+ T-cells,
this impairment was responsible for the IDO-dependent
immune suppression [22]. Our previous study also showed2 Clinical and Developmental Immunology
that exposure to the milieu created by an IDO-positive
nasopharyngeal carcinoma cell line signiﬁcantly impaired
the lymphocyte cytotoxicity against target tumor cells [23].
Ap r e v i o u ss t u d yo nas m a l lg r o u po fE S C Cp a t i e n t s
showed that IDO mRNA was expressed in ESCC tumor
specimens, and ESCC patients with higher levels of IDO
mRNA expression had a worse survival rate than those with
lower levels of IDO mRNA expression [24]. In contrast, Liu
reported that the level of IDO expression did not correlate
with the clinic outcomes of ESCC patients [25]. In the
current study, we investigated the relationship between IDO
expression and the degree of tumor inﬁltration of CD8+ T
cells,andtheclinicalsigniﬁcanceofIDOexpressioninESCC.
We also explored the eﬀect of IDO on the proliferation and
function of CD8+ TILs in ESCC.
2.MaterialsandMethods
2.1.Patients. Atotalof135ESCCsampleswerehistologically
and clinically diagnosed when the patients with primary
ESCC underwent radical esophagectomy between 2001 and
2004 at the Cancer Center of Sun Yat-sen University. No
patients had received prior anticancer treatment. Prior to
the use of these clinical materials for investigation, informed
consent from patients and approval from the Institute
Research Ethics Committee were obtained. The clinical
typing of the tumors was determined according to the
pathological TNM classiﬁcation [26]. Clinical information
of the samples is described in detail in Table 1. The numbers
undergoing metastasis pertain to the presence of metastasis
at any time during follow-up. The median followup time for
overall survival was 49.0 months for patients still alive at the
time of analysis, and the time ranged from 7 to 78 months. A
total of 91 (67.4%) patients died during followup.
2.2. Immunohistochemistry and Immunoblotting. Immuno-
histochemistryandwesternblotwereperformedasdescribed
previously [23, 27]. For immunohistochemistry, an anti-
IDO polyclonal antibody (1:500, generated in our labo-
ratory [23]) and a mouse monoclonal anti-CD8 (1:150,
BD Pharmingen) were incubated with the tissue sections
overnightat4◦C.Fornegativecontrols,theprimaryantibody
was replaced by normal rabbit or mouse serum. After
washing, tissue sections were treated with biotinylated anti-
mouse or anti-rabbit antibody (Zymed), followed by further
incubationwithstreptavidinHRPcomplex.ForWesternblot
analysis, IDO was detected using an anti-IDO polyclonal
antibody (1:5,000). An anti-β-actin monoclonal antibody
(1:5,000) was used to conﬁrm equal loading.
2.3. Scoring of IDO Expression in Tumor Cells. The degree
of immunostaining was reviewed and scored by two inde-
pendent observers, as described previously [28]. According
to the percent of positive cells, one score was given for
each as follows: <5% of the cells = 1 point; 6–35% of the
cells = 2 points; 36–70% of the cells = 3 points; >70% of the
cells = 4 points. Another score was given according to the
intensity of staining as follows: negative staining = 1 point;
weak staining (light yellow) = 2 points; moderate staining
(yellowish brown) = 3 points; strong staining (brown) =
4 points. A ﬁnal score was then calculated by multiplying
the above two scores. If the ﬁnal score was ≥4, the tumor
was considered high expression; otherwise, the tumor was
considered low expression. IDO expression in tumor stromal
cells was not considered because IDO immunostaining on
nontumor cells was not remarkable in all cases examined.
2.4. Quantiﬁcation of TIL Cells within ESCC. CD8+ TILs
were classiﬁed into two groups by their localization: (a)
intraepithelial, cells inﬁltrating into the tumor epithelium;
(b) stromal, cells inﬁltrating the tumor stroma adjacent to
cancer epithelia or the stroma along the invasive margin of
the cancer epithelia. Quantiﬁcation of CD8+ TILs was done
according to the previous reports of Cho and Schumacher
with some modiﬁcations [6, 7]. Three independent areas
with the most abundant CD8+ TIL inﬁltration were selected,
and the intraepithelial CD8+ TILs and stromal CD8+ TILs
were independently counted in each microscopic ﬁeld at
200 × (0.0625mm2). The average count for three areas was
accepted as the number of CD8+ TILs in each case. We clas-
siﬁed patients into two groups by intraepithelial CD8+ TIL
counts: the high intraepithelial CD8+ TIL group (mean ≥
10) and low intraepithelial CD8+TIL group (mean < 10). On
the basis of stromal CD8+TIL counts, patients were classiﬁed
into two groups in the same manner: the high stromal CD8+
group (mean ≥ 20) and low stromal CD8+ group (mean <
20).
2.5. ESCC Cell Culture and CD8+ T-Cell Isolation. The ESCC
cell lines Eca109, TE-1, and KYSE140 (Cell Bank of Type
Culture Collection of Chinese Academy of Sciences) were
grown in RPMI 1640 (Invitrogen) supplemented with 10%
fetalbovineserum.IFNγ (ChinaNationalBiotecGroup)was
added to the medium at 0–500U/mL, for the indicated time.
Peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood of patients with ESCC before surgical
treatmentbyFicolldensitygradient(Sigma-Aldrich).Forthe
isolation of TILs, fresh tumor tissues from ESCC patients
who underwent surgical treatment at our hospital were
ﬁnely minced and subjected to enzymatic digestion. The
resultant suspensions were ﬁltered through a 25μmm e s h
ﬁlter, and the single-cell ﬁltrate was washed twice in PBS
followed by Ficoll/Hypaque puriﬁcation. The isolation of
CD8+ T lymphocytes from PBMCs and TILs was performed
by means of immunomagnetic beads using a Dynal CD8
positive isolation kit (Invitrogen Dynal). Purity of CD8+ was
>98% CD8+ as checked by ﬂow cytometry and CD8+ Tc e l l s
were grown in complete RPMI 1640 medium.
2.6. Measurement of IDO Activity. Trp and Kyn concentra-
tions were analyzed by reverse-phase high-performance liq-
uidchromatography(HPLC;Waters)asdescribedpreviously
[23]. IDO activity was determined by the Kyn to Trp ratio
(Kyn/Trp, μM/μM).
2.7. Cell Proliferation, Apoptosis, and Cytotoxicity Assay.
Eca109cellswereculturedin6-wellplates(3 ×105 cells/well)Clinical and Developmental Immunology 3
Table 1: Characteristics of 135 patients with esophageal squamous cell carcinoma and correlation between the clinicopathologic features
and expression of IDO.
Characteristics All cases (n)I D O l o w n ( %) IDO high n ( %) Signiﬁcance (P)∗
Gender
Male 100 45 (45.0) 55 (55.0) 0.069
Female 35 22 (62.9) 13 (37.1)
Age (y)
<60 80 35 (43.8) 45 (56.2) 0.100
≥60 55 32 (58.2) 23 (41.8)
Stage
I-II 74 45 (60.8) 29 (39.2) 0.004
III-IV 61 22 (36.1) 39 (63.9)
Histological diﬀerentiation
Well 41 25 (61.0) 16 (39.0) 0.075
Moderate 57 22 (38.6) 35 (61.4)
Poor 37 20 (54.1) 17 (45.9)
Tumor diameter
<40mm 54 25 (46.3) 29 (53.7) 0.527
≥40mm 81 42 (51.9) 39 (48.1)
Depth of invasion
Submucosa 7 5 (71.4) 2 (28.6) 0.300
Muscularis propria 46 25 (54.3) 21 (45.7)
Adventitia 82 37 (45.1) 45 (54.9)
pT classiﬁcation
T1-T2 44 28 (63.6) 16 (36.4) 0.024
T3-T4 91 39 (42.9) 52 (57.1)
pN classiﬁcation
Yes 65 25 (38.5) 40 (61.5) 0.012
No 70 42 (60.0) 28 (40.0)
Pm e t a s t a s i s
Yes 9 4 (44.4) 5 (55.6) 0.982
No 126 63 (50.0) 63 (50.0)
Intraepithelial CD8+
High (≥10) 62 38 (61.3) 24 (38.7) 0.013
Low (<10) 73 29 (39.7) 44 (60.3)
Stromal CD8+
High (≥20) 66 42 (63.6) 24 (36.4) 0.001
Low (<20) 69 25 (36.2) 44 (63.8)
in the absence or presence of 50-U/mL IFNγ for 12hr,
and the medium was then replaced by fresh medium
with or without 100μM 1-methyl-L-tryptophan (1MT,
Sigma-Aldrich). Then, 24hr after medium replacement,
the culture media were harvested as Eca109-conditioned
media(Eca109-CMs).CD8+ T-cellproliferationwasassessed
by standard thymidine incorporation assay as described
previously [29]. Brieﬂy, 1 × 105 CD8+ T cells were cultured
in Eca109-CMs and stimulated with plate-bound anti-CD3
mAb (OKT3, ATCC) and soluble anti-CD28 mAb (BD
Bioscience). After 72 hours of culture, 1-μCi 3[H] thymidine
was added, and incorporation was measured after 24hr in
a β-Counter (Wallac). The proportion of apoptotic cells
from diﬀerent culture conditions were examined by ﬂow
cytometry using an Annexin V-FITC apoptosis detection kit
(Beckman Coulter).
The cytotoxic activity of CD8+ T cells was determined by
a standard lactate dehydrogenase (LDH) release assay using
the CytoTox 96 (Promega) as previously described [23].
Brieﬂy, the Eca109 cells (5 × 103 cells/well) were cultured
as target cells. IL-2-stimulated CD8+ T cells were incubated
in diﬀerent Eca109-CMs as the treated eﬀector cells. The
target cells and eﬀector cells suspensions were cocultured
at various indicated eﬀector:target (E/T) ratios. After 4h
of incubation, the release of LDH into the supernatant
was quantiﬁed by recording the absorbance at 490nm. The4 Clinical and Developmental Immunology
percentage of cytotoxicity was calculated as manufacturer
described.
2.8. Statistical Analysis. All statistical analyses were con-
ducted using the SPSS 16.0 statistical software package.
Parametrically distributed data are presented as mean ± SD.
Comparison of the number of CD8+ TILs in the IDO-low
group and IDO-high group was performed with the Mann-
Whitney U test. The Pearson χ2 and Fisher’s exact test were
used to analyze the relationship between IDO expression
and clinicopathologic characteristics or the number of CD8+
TILs. Survival curves were plotted by the Kaplan-Meier
method and compared by the log-rank test. Comparison
between paired or unpaired groups was performed using the
appropriate Student’s t-test. A P value of < 0.05 in all cases
was considered statistically signiﬁcant.
3. Results
3.1. Expression of IDO in Archival Esophageal Tumor Tis-
sues and Association of IDO Expression with CD8+TILs.
IDO protein was detected in all 135 paraﬃn-embedded
archived ESCC tissues (100%) by immunohistochemistry.
IDO immunoreactivity was observed at various levels, and
localization was observed in the cytoplasm of the tumor
cells. By visual estimation, tumors were grouped into two
categories: “IDO-high expression” and “IDO-low expres-
sion”accordingtoaproportionandintensityscoredescribed
in Methods (Figures 1(a)–1(d)). IDO was highly expressed
in 68 of 135 (50.4%) tumor tissues, whereas 67 of 135
(49.6%)casesshowedlowIDOexpressionlevels(Table 1).In
contrast, in the normal esophageal tissue adjacent to cancers,
IDO had absent to weak staining patterns (Figures 1(e)–
1(f)).
To investigate the relationship between IDO expression
and the CD8+ TIL population, we evaluated the number
of CD8+ TIL inﬁltrating into the tumor epithelium or
stroma (Figures 1(g)–1(j)). The number of intraepithelial
CD8+ TILs in IDO-high expressing tumors (range 1–
22; median10.6) was signiﬁcantly lower than in IDO-
low expressing tumors (range 6–37; median 21.1; P =
0.013; Figure 2(a)). Similarly, IDO-high expressing tumors
exhibited a signiﬁcantly lower proportion of stromal CD8+
TILs (range 7–36; median 20.1) compared with IDO-low
expressing tumors (range 18–62; median 41.2; P = 0.001;
Figure 2(b)). The correlation of IDO expression and CD8+
TIL counts is summarized in Table 1. These results suggest
that the level of IDO expression is inversely correlated with
the number of intraepithelial CD8+ TILs and the number of
stromal CD8+ TILs.
3.2. Association of IDO Expression with Clinicopathological
Variables. As shown in Table 1, there was no signiﬁcant
correlation between the expression level of IDO protein
and gender, age, histological classiﬁcation, histological dif-
ferentiation, tumor diameter, depth of invasion, and dis-
tant metastasis of esophageal cancer patients. However,
the expression of IDO is closely associated with stage of
esophageal cancer patients (P = 0.004), T classiﬁcation (P =
0.024), and pN classiﬁcation (P = 0.012). Higher staging,
higher T classiﬁcation and lymph node metastasis correlated
with higher IDO expression.
3.3. Impact of IDO Expression and CD8+ TIL Counts on
Patient Overall Survival. Overall survival analysis according
to Kaplan-Meier analysis showed that although survival
curves crossed at 73 months, the expression of IDO protein
in esophageal carcinoma was signiﬁcantly correlated with
patients’ survival time (P=0.041), indicating that higher
levels of IDO expression was correlated with shorter survival
time whereas the low-IDO expression group had better
survival (Figure 3(a)). The median survival of patients with
high IDO expression was much shorter (23 months) than
those with low IDO expression (33 months).
Next, we analyzed the eﬀect of the CD8+ TIL counts
on patient survival. Figure 3(b) showed that patients in
the high intraepithelial CD8+ TIL groups (≥10) showed
a signiﬁcantly higher survival time compared with those
in the low intraepithelial CD8+ TIL groups (<10; P =
0.043). Similarly, those in the high stromal CD8+ TIL
groups (≥20) exhibited a signiﬁcantly higher survival time
compared with those in the low stromal CD8+ TIL groups
(<20; P = 0.024; Figure 3(c)). These results indicated that
patients with low intraepithelial and stromal CD8+ TILs had
signiﬁcantly impaired survival compared with patients with
high intraepithelial and stromal CD8+ TILs.
3.4. IDO Expression in Esophageal Carcinoma Cell Lines and
Induction by IFNγ. The eﬀect of IFNγ on IDO expression
was investigated in the ESCC cell lines: Eca109, TE-1, and
Kyse140. As shown in Figure 4(a), the western blot assay
showed that none of the cell lines constitutively expressed
the IDO protein. IDO could be induced in these cell
lines by treatment with 100-U/mL IFNγ. Among these cell
lines, Eca109 had the highest expression level. Then, we
performed western blot analysis to investigate the eﬀects
of varying concentrations of IFNγ on the expression of
IDO in Eca109 cells. Figure 4(b) shows that treatment with
low-dose IFNγ (10U/mL) could induce IDO expression,
which was further increased in an IFNγ concentration-
dependent manner. The enzymatic activity of IDO was also
investigated by HPLC (Figure 4(c)). The enzymatic activity
of IDO was undetectable in the culture medium of untreated
Eca109 cells, but the activity was observed with 10U/mL
IFNγ stimulation, peaking with 50U/mL IFNγ, and then
it remained at almost the same level with increasing IFNγ
stimulation. Thus, consistent with the results of the western
blot analysis, IDO expression in ESCC cell lines was an
inducibleeventthatwashighlysensitivetoIFNγ stimulation.
3.5. Exposure to the Microenvironment Created by IDO-
PositiveEca109CellsSeverelySuppressesCD8+T CellsProlifer-
ation and Does Not Induce CD8+T Cell Apoptosis. To address
our above observations that the samples with a high IDO
expression also had a low number of CD8+ TILs, we tested
whether the exposure to CM from IFNγ-treated Eca109 cells
could inhibit CD8+ T-cell proliferation and/or induce CD8+
T-cell apoptosis. We treated Eca109 cells with or withoutClinical and Developmental Immunology 5
(a) (b)
(c) (d)
(e) (f)
(g) (h)
(i) (j)
Figure 1: Expression analysis of IDO protein in ESCC by immunohistochemistry and representative immunohistochemical staining for
CD8+ TILs. (a, b) Example of IDO-low expression. (c, d) Example of IDO-high expression. (e, f) Staining of IDO in normal esophageal
epithelial tissue, (e) absent; (f) weak. (g) Example of stromal CD8+ TIL staining in IDO-low expression tumor tissue. (h) Example of
intraepithelial CD8+ TIL staining in IDO-low expression tumor tissue. (i) Example of stromal CD8+ TIL staining in IDO-high expression
tumor tissue. (j) Example of intraepithelial CD8+ TIL staining in IDO-high expression tumor tissue (original magniﬁcation, (a) and
(c) ×100; (b, d, e–j) ×200).6 Clinical and Developmental Immunology
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Figure 2: Association of IDO expression with the number of CD8+ TILs. There was a signiﬁcant diﬀerence in both the number of
intraepithelial CD8+ TILs (a) and stromal CD8+ TILs (b) between the tissues with IDO-high expression and IDO-low expression.
IFNγ before CD8+ T cells were cultured in these CMs under
anti-CD3/CD28 mAb stimulation. CD8+ T-cell proliferation
bothfromPBMCsandTILswassigniﬁcantlylowerintreated
media compared with the proliferation in untreated media
(Figure 5(a)). These ﬁndings indicated that the CM derived
from IFNγ–treated Eca109 cells suppressed CD8+ T-cell
proliferation. Next, we tested whether the observed eﬀects
of the CM on CD8+ T-cell proliferation rates were related
to functional IDO enzyme activity. As shown in Figure 5(b),
IFNγ–treated Eca109 cells had IDO enzyme activity whereas
untreated cells did not have IDO enzyme activity. To further
demonstrate the eﬀect of IDO on the proliferation of CD8+T
cells, the speciﬁc IDO inhibitor 1MT was used to block the
enzyme activity. When exposed to IFNγ-treated Eca109-CM,
the proliferation of CD8+ T cells both from PBMCs and
TILs was almost completely restored by the 1MT addition
(Figure 5(a)), the functional IDO enzyme activity in IFNγ-
treated Eca109-CM was dramatically inhibited by the 1MT
(Figure 5(b)). Taken together, the data indicated that the
mediacreatedbyIDO-positiveEca109cellssuppressedCD8+
T-cell proliferation in vitro.
We next aimed to determine the eﬀects of IDO on
apoptosis of CD8+ T cells. Without simulation, CD8+ T
cells from both PBMCs and TILs exhibited no signiﬁcant
diﬀerence in the frequency of apoptotic cells between the
cells exposed to IFNγ-treated and untreated Eca109-CM.
Similarly, under anti-CD3/CD28 simulation, there was no
signiﬁcant diﬀerence in the frequency of apoptotic cells
between the cells exposed to IFNγ-treated and untreated
Eca109-CM (Figure 5(c)). These results indicated that IDO
derivedfromIFNγ-treatedEca109cellsexertednosigniﬁcant
impact on the apoptosis of CD8+ T cells.
3.6. Exposure to Conditioned Medium Derived from IDO-
Positive Eca109 Cells Impairs Cytolytic Activity of CD8+ T
Cells. To investigate whether IDO has an eﬀect on the
c y t o l y t i ca c t i v i t yo fC D 8 + T cells, a standard LDH release
assay was conducted using Eca109 cells as targets and CD8+
T cells from PBMCs or from TILs stimulated by IL-2 as
eﬀectors. IL-2 activated CD8+ T cells from both PBMCs
and TILs lysed the target cells at diﬀerent E/T ratios when
exposedtoCMsfromuntreatedEca109cellswhereasthelysis
rate was remarkably reduced when the T cells were exposed
to IFNγ-treated Eca109-CMs. But the cytolytic activity of
CD8+ T cells from both PBMCs and TILs was eﬀectively
restored when exposed to CM derived from IFNγ-treated
Eca109 cells and in the presence of 1MT (Figures 6(a) and
6(b)). Because the IDO enzyme activity only presented in
CM from IFNγ-treated Eca109 cells, but not in CM from
untreated cells or dramatically reduced in CM from IFNγ-
treated Eca109 cells with 1MT (Figure 6(c)). These results
suggested that the inhibition on CD8+ T cell-mediated
cytotoxicity was attributed to IDO created by IFNγ-treated
Eca109 cells, and 1MT can abrogate this eﬀect, providing
a potential role of IDO in impairing CD8+ T-cell cytotoxic
function.
4. Discussion
In this study, we conﬁrmed previous reports that ESCC
patients with higher numbers of CD8+ TILs within either
tumor epithelium or tumor stroma had a better prognosis
than those with a lower number of CD8+ TILs [6, 7]. Recent
studies have suggested that tumoral IDO expression corre-
lates with a reduced number of CD8+ T-cell inﬁltration into
tumor sites [8–10]. In line with these observations, we also
found that IDO expression in ESCC was inversely correlated
with the number of CD8+ TILs both in tumor epithelium
and tumor stroma. Moreover, our data indicated that the
expression of IDO correlated with the poor clinical outcome
of ESCC patients and are consistent with a previous study
that ESCC patients with higher levels of IDO expression hadClinical and Developmental Immunology 7
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Figure 3: Overall survival curves drawn using Kaplan-Meier method according to the IDO expression, the number of intraepithelial CD8+
TILs and the number of stromal CD8+ TILs in 135 ESCC patients. (a) There was a signiﬁcant diﬀerence in the overall survival between
patients with low IDO expression (bold lines) and high IDO expression (dotted lines). (b) Signiﬁcant diﬀerences in overall survival between
the high intraepithelial CD8+ TIL groups (≥10) and the low intraepithelial CD8+ TIL groups (<10). (c) Signiﬁcant diﬀerences in overall
survival between the high stromal CD8+ TIL groups (≥20) and the low stromal CD8+ TIL groups (<20).8 Clinical and Developmental Immunology
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Figure 4: Eﬀect of IFNγ on IDO expression in the esophageal carcinoma cell lines. Esophageal carcinoma cell lines Kyse 140, TE-1, and
Eca109 were treated with or without 100U/mL IFNγ for 24 hr, and expression of the IDO protein was assessed by western blot (a). IFNγ
induced IDO protein expression in Eca109 cells in a dose-dependent manner. Eca109 cells were cultured in the presence of indicated
concentrations of IFNγ for 24hr, IDO expression was analyzed by western blotting (b); the supernatants of Eca109 cells were analyzed
for Kyn and Trp production using HPLC (c). Columns, mean of three independent experiments. Bars, SD.
a worse survival rate than patients with lower levels of IDO
expression [24]. However, these results were in contrast with
thoseofLiuetal.inthatIDOexpressionwasnotsigniﬁcantly
correlated with clinical outcomes [25]. The less marked
impact of IDO on clinical outcomes reported by Liu et al.
might be due to the comparatively small patient population
analyzed. Consistent with other studies that serum/plasma
Kyn/Trp levels were used as indicator of IDO activity and
were found higher IDO enzyme activity predicted worse
survival of cancer patients [8, 30]. Our ﬁndings also suggest
that higher tumoral IDO expression and lower numbers of
CD8+ TILs might contribute to a worse survival in ESCC
patients.
IDO is widely distributed in mammals and is prefer-
entially inducible by IFNγ [11] .T h e r eh a v eb e e ns t u d i e s
indicating that IDO is upregulated in many tumor cell lines
only upon treatment with IFNγ and/or other inﬂammatory
mediators [31, 32]. Recently, Godin-Ethier reported that
activated T cells induce functional IDO expression in breast
and kidney tumor cell lines and that this was partly
attributable to IFNγ [13]. In the present study, an analysis of
Kyn production demonstrated that IDO enzymatic activity
was only present in the esophageal cancer cell lines treated
with IFNγ, and western blot also conﬁrmed the ﬁnding. Fur-
thermore, we showed that IFNγ induced the IDO expression
inEca109cellsatconcentrationsaslowas10U/mL,implying
that IDO expression in Eca109 cells could be easily induced
by low levels of IFNγ. The ﬁnding that ESCC tumor cell
lines show no constitutive IDO expression and that only
IFNγ was able to induce huge activity corresponds very well
to early Werner-Felmayer’s study [33], but is a little against
claims made by Uyttenhove [12]. This discrepancy may be
the diﬀerent tumor cell lines used in diﬀerent studies.
Tumor-associated antigen-presenting cells, such as
macrophages and dendritic cells, and tumor-associated
antigen-speciﬁc T-cells within the tumor microenvironment
release this cytokine [34]; thus, they might induce IDO
expression in esophageal tumor cells in vivo.
Once expressed in tumor cells, IDO degrades the essen-
tial amino acid Try to form N-formyl Kyn and produces
as e r i e so fi m m u n o s u p p r e s s i v eT r ym e t a b o l i t e s[ 12]. Two
apparently disparate mechanisms have been proposed to
explain how IDO plays a role in immune suppression. One
suggests that depleting local L-Try, an essential amino acid
for T-cell proliferation, may block the cell cycle in the G1
phase and render T cells susceptible to proliferation arrest
[12, 35, 36], and the other suggests that IDO may suppress
T-cell responses by the action of Try metabolites, such as
Kyn, which are toxic and proapoptotic for T cells [19]. Our
data showed that exposure to the microenvironment created
by IDO-positive Eca109 cells severely suppressed CD8+ T-
cell proliferation and did not signiﬁcantly induce CD8+ T-
cell apoptosis, and the results favor the model describing
the proliferation arrest of CD8+ T cells. Thus, the inhibitionClinical and Developmental Immunology 9
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Figure 5: Eﬀect of IDO on the proliferation and apoptosis of CD8+ T cells from both PBMCs and TILs. (a) Proliferation of CD8+ Tc e l l s
from PBMCs or TILs was suppressed by IDO-expressing Eca109 cells. CD8+ T cells were cultured in conditioned media and activated
with anti-CD3/CD28 antibodies. Proliferation of CD8+ T cells was assayed by [3H] TdR incorporation. (b) Concentrations of Kyn and Try
were measured in the supernatants of Eca109 cells treated with or without IFNγ (50U/mL) and/or 1MT (100μM) for 24hr. Kyn and Try
productions were analyzed by HPLC. (c) Eﬀe c to fI D Oo nt h ea p o p t o s i so fC D 8 + T cells from PBMCs or TILs. CD8+ T cells (1–4) or anti-
CD3/CD28-activatedCD8+ Tcells(5–8)frombothPBMCsandTILswereculturedinconditionedmediaderivedfromIFNγ-treated(2,4,6,
8) or untreated (1, 3, 5, 7) Eca109 cells for 4d, and the population of apoptotic cells was detected by ﬂow cytometric analysis, using Annexin
V and Propidium Iodide as indicators. Columns, mean of three independent experiments. Bars, SD. ∗P < 0.05 compared with CD8+ Tc e l l s
cultured in conditioned media derived from non-IFNγ-treated Eca109 cells.
of CD8+ T cell proliferation locally by IDO expression in
ESCCtumorcellsmaycontributetothehighIDOexpression
correlatedwithlownumbersofCD8+ TILsbothinthetumor
epithelium and tumor stroma.
In addition, we presented the evidence that exposure
to IDO-expressing Eca109-CM dramatically weakened the
c y t o l y t i cf u n c t i o no fC D 8 + T cells from both PBMCs and
TILs against target cells, but this attenuation could be
abrogated by the addition of the IDO inhibitor 1MT. In line
withourobservations,Liuetal.veryrecentlyreportedthatin
theexperimentalratlungallograftmodel,IDOcreatesalocal
microenvironment that leads to not only reduction in the
numbers of CD8+ TILs, but also the loss of cytotoxic activity
of the CD8+ eﬀector T cells toward target cells [22]. The
impaired cytotoxic function seen in the IDO-treated CD8+
T cells was accompanied by defects in the production of10 Clinical and Developmental Immunology
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Figure 6: Cytolytic activity of CD8+ T cells from both PBMCs and TILs was impaired by incubation with media created by IDO-positive
Eca109 cells. Activated CD8+ T cells from both PBMCs (a) and TILs (b) were cultured with CM from Eca109 cells treated with or without
50-U/mL IFNγ and/or 100-μM 1MT for 24hr, and cytolytic activity against Eca109 cells was evaluated using a standard LDH release assay.
The E/T ratios are indicated. (c) Eca109 cells were treated with or without 50-U/mL IFNγ and/or 100-μM 1MT for 24hr. The Eca109
cell supernatants were analyzed for Kyn/Try production by HPLC. Columns, mean of three independent experiments. Bars, SD. ∗P < 0.05
compared with CD8+ T cells cultured in conditioned media derived from non-IFNγ-treated Eca109 cells.
granule cytotoxic proteins, including perforin and granzyme
A and B. Moreover, IDO leads to an impaired bioenergetic
condition in active CD8+ T cells via selective inhibition
of complex I in the mitochondrial electron transfer chain
[22]. Our previous study also showed that exposure to the
milieu created by IDO-positive nasopharyngeal cancer cells
signiﬁcantly impaired lymphocytes against target tumor cells
[23]. These ﬁndings, together with our observations, suggest
that IDO creates an immune suppression microenvironment
not only by suppressing the proliferation of CD8+ TILs
but also by impairing the cytotoxic function of CD8+ TILs.
However, further studies are needed to elucidate the exact
mechanisms of how IDO expressed by ESCC tumor cells
reduces the cytotoxicity of CD8+ T cells.
In conclusion, IDO expression in ESCC correlated with
the reduced number of CD8+ TILs, which is associated with
disease progression and worse clinical outcome, may largely
be due to the IDO-mediated proliferation arrest of CD8+
TILs. Moreover, the CD8+ T cells exposed to the milieu
generated by IDO-expressing Eca109 cells lost their cytolytic
function. We suggest that the eﬀect of IDO expressed in
ESCC cells on the proliferation and cytolytic function of
CD8+ TILs could contribute to the ﬁnding that patients
with higher IDO expression have more aggressive disease
progression and a shorter overall survival time. Although
the precise role of tumoral IDO in human ESCC remains
to be elucidated, our ﬁndings suggest that blocking IDO
activity may provide a potential means of restoring the host
antitumor immunity in the treatment of ESCC.
Acknowledgments
This paper was supported by National Natural Science
Foundation of China (no. 81072670; no. 30972762) and 973Clinical and Developmental Immunology 11
Program (no. 2011CB935800). Ge Zhang and Wan-Li Liu
contributed equally to this paper.
References
[1] T. Boon and P. Van der Bruggen, “Human tumor antigens rec-
ognized by T lymphocytes,” Journal of Experimental Medicine,
vol. 183, no. 3, pp. 725–729, 1996.
[2] P. van der Bruggen and B. J. Van den Eynde, “Processing and
presentation of tumor antigens and vaccination strategies,”
Current Opinion in Immunology, vol. 18, no. 1, pp. 98–104,
2006.
[ 3 ]C .M .B a l c h ,L .B .R i l e y ,Y .J .B a ee ta l . ,“ P a t t e r n so f
human tumor-inﬁltrating lymphocytes in 120 human can-
cers,” Archives of Surgery, vol. 125, no. 2, pp. 200–205, 1990.
[4] K. M. Ropponen, M. J. Eskelinen, P. K. Lipponen, E. Alhava,
and V. M. Kosma, “Prognostic value of tumour-inﬁltrating
lymphocytes (TILs) in colorectal cancer,” Journal of Pathology,
vol. 182, no. 3, pp. 318–324, 1997.
[5] Y. Naito, K. Saito, K. Shiiba et al., “CD8+ T cells inﬁltrated
within cancer cell nests as a prognostic factor in human
colorectal cancer,” Cancer Research, vol. 58, no. 16, pp. 3491–
3494, 1998.
[ 6 ] Y .C h o ,M .M i y a m o t o ,K .K a t oe ta l . ,“ C D 4 + and CD8+ Tc e l l s
cooperate to improve prognosis of patients with esophageal
squamous cell carcinoma,” Cancer Research, vol. 63, no. 7, pp.
1555–1559, 2003.
[7] K. Schumacher, W. Haensch, C. R¨ oefzaad, and P. M. Schlag,
“Prognostic signiﬁcance of activated CD8+ T cell inﬁltrations
within esophageal carcinomas,” Cancer Research, vol. 61, no.
10, pp. 3932–3936, 2001.
[8] G. Brandacher, A. Perathoner, R. Ladurner et al., “Prognostic
value of indoleamine 2,3-dioxygenase expression in colorectal
cancer: eﬀect on tumor-inﬁltrating T cells,” Clinical Cancer
Research, vol. 12, no. 4, pp. 1144–1151, 2006.
[9] T. Inaba, K. Ino, H. Kajiyama et al., “Role of the immunosup-
pressive enzyme indoleamine 2,3-dioxygenase in the progres-
sionofovariancarcinoma,”GynecologicOncology,vol.115,no.
2, pp. 185–192, 2009.
[10] K. Ino, E. Yamamoto, K. Shibata et al., “Inverse correlation
betweentumoralindoleamine2,3-dioxygenaseexpressionand
tumor-inﬁltrating lymphocytes in endometrial cancer: its
association with disease progression and survival,” Clinical
Cancer Research, vol. 14, no. 8, pp. 2310–2317, 2008.
[11] D. H. Munn and A. L. Mellor, “Indoleamine 2,3-dioxygenase
and tumor-induced tolerance,” Journal of Clinical Investiga-
tion, vol. 117, no. 5, pp. 1147–1154, 2007.
[12] C. Uyttenhove, L. Pilotte, I. Th´ eate et al., “Evidence for
a tumoral immune resistance mechanism based on trypto-
phan degradation by indoleamine 2,3-dioxygenase,” Nature
Medicine, vol. 9, no. 10, pp. 1269–1274, 2003.
[13] T .G u,R.B .R o w sw ell-T urne r ,M.O .K ilinc,andN.K.E gilmez,
“Central role of IFNγ-indoleamine 2,3-dioxygenase axis in
regulation of interleukin-12-mediated antitumor immunity,”
Cancer Research, vol. 70, no. 1, pp. 129–138, 2010.
[14] J. Godin-Ethier, S. Pelletier, L. A. Hanaﬁ et al., “Human
activated T lymphocytes modulate IDO expression in tumors
through Th1/Th2 balance,” Journal of Immunology, vol. 183,
no. 12, pp. 7752–7760, 2009.
[15] A. Okamoto, T. Nikaido, K. Ochiai et al., “Indoleamine 2,3-
dioxygenase serves as a marker of poor prognosis in gene
expression proﬁles of serous ovarian cancer cells,” Clinical
Cancer Research, vol. 11, no. 16, pp. 6030–6039, 2005.
[16] K. Ino, N. Yoshida, H. Kajiyama et al., “Indoleamine 2,3-
dioxygenase is a novel prognostic indicator for endometrial
cancer,” British Journal of Cancer, vol. 95, no. 11, pp. 1555–
1561, 2006.
[17] V. Karanikas, M. Zamanakou, T. Kerenidi et al., “Indoleamine
2,3-dioxygenase (IDO) expression in lung cancer,” Cancer
Biology and Therapy, vol. 6, no. 8, pp. 1258–1262, 2007.
[18] H. Urakawa, Y. Nishida, H. Nakashima, Y. Shimoyama, S.
Nakamura, and N. Ishiguro, “Prognostic value of indoleamine
2,3-dioxygenase expression in high grade osteosarcoma,”
Clinical and Experimental Metastasis, vol. 26, no. 8, pp. 1005–
1012, 2009.
[19] F. Fallarino, U. Grohmann, C. Vacca et al., “T cell apoptosis by
tryptophan catabolism,” Cell Death and Diﬀerentiation, vol. 9,
no. 10, pp. 1069–1077, 2002.
[20] A. L. Mellor and D. H. Munn, “IDO expression by dendritic
cells: tolerance and tryptophan catabolism,” Nature Reviews
Immunology, vol. 4, no. 10, pp. 762–774, 2004.
[21] D. H. Munn, E. Shaﬁzadeh, J. T. Attwood, I. Bondarev, A.
Pashine, and A.L. Mellor, “Inhibition of T cell proliferation by
macrophage tryptophan catabolism,” Journal of Experimental
Medicine, vol. 189, no. 9, pp. 1363–1372, 1999.
[22] H. Liu, L. Liu, K. Liu, P. Bizargity, W. W. Hancock, and G. A.
Visner, “Reduced cytotoxic function of eﬀector CD8+ T cells
is responsible for indoleamine 2,3-dioxygenase-dependent
immune suppression,” Journal of Immunology, vol. 183, no. 2,
pp. 1022–1031, 2009.
[23] P. Liu, B. L. Xie, S. H. Cai et al., “Expression of indoleamine
2,3-dioxygenase in nasopharyngeal carcinoma impairs the
cytolytic function of peripheral blood lymphocytes,” BMC
Cancer, vol. 9, article no. 416, 2009.
[24] K. Sakurai, K. Enomoto, S. Amano et al., “Study of
indoleamine 2,3-dioxygenase expression in patients of
esophageal squamous cell carcinoma,” Gan To Kagaku Ryoho,
vol. 31, no. 11, pp. 1780–1782, 2004.
[25] J. Liu, G. Lu, F. Tang, Y. Liu, and G. Cui, “Localization of
indoleamine 2,3-dioxygenase in human esophageal squamous
cell carcinomas,” Virchows Archiv, vol. 455, no. 5, pp. 441–448,
2009.
[26] L. H. Sobin and I. D. Fleming, “TNM classiﬁcation of
malignant tumors, Fifth edition,” Cancer,v o l .8 0 ,n o .9 ,p p .
1803–1804, 1997.
[27] X. Z. Guo, G. Zhang, J. Y. Wang et al., “Prognostic relevance of
Centromere protein H expression in esophageal carcinoma,”
BMC Cancer, vol. 8, article no. 233, 2008.
[28] W.L.Liu,X.Z.Guo,L.J.Zhangetal.,“Prognosticrelevanceof
Bmi-1 expression and autoantibodies in esophageal squamous
cell carcinoma,” BMC Cancer, vol. 10, article no. 467, 2010.
[29] A. L. Mellor, D. B. Keskin, T. Johnson, P. Chandler, and D. H.
Munn, “Cells expressing indoleamine 2,3-dioxygenase inhibit
T cell responses,” Journal of Immunology, vol. 168, no. 8, pp.
3771–3776, 2002.
[30] G.Weinlich,C.Murr,L.Richardsen,C.Winkler,andD.Fuchs,
“Decreased serum tryptophan concentration predicts poor
prognosisinmalignantmelanomapatients,”Dermatology,vol.
214, no. 1, pp. 8–14, 2006.
[31] M. W. Taylor and G. Feng, “Relationship between interferon-
γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism,”
FASEB Journal, vol. 5, no. 11, pp. 2516–2522, 1991.
[32] A. J. Muller, M. D. Sharma, P. R. Chandler et al., “Chronic
inﬂammation that facilitates tumor progression creates local
immune suppression by inducing indoleamine 2,3 dioxyge-
nase,” Proceedings of the National Academy of Sciences of the12 Clinical and Developmental Immunology
United States of America, vol. 105, no. 44, pp. 17073–17078,
2008.
[33] G. Werner-Felmayer, E. R. Werner, D. Fuchs, A. Hausen, G.
Reibnegger, and H. Wachter, “Characteristics of interferon
induced tryptophan metabolism in human cells in vitro,”
Biochimica et Biophysica Acta, vol. 1012, no. 2, pp. 140–147,
1989.
[ 3 4 ]A .J .M u l l e r ,J .B .D u H a d a w a y ,M .Y .C h a n ge ta l . ,“ N o n -
hematopoietic expression of IDO is integrally required
for inﬂammatory tumor promotion,” Cancer Immunology,
Immunotherapy, vol. 59, no. 11, pp. 1655–1663, 2010.
[35] G. P. Dunn, C. M. Koebel, and R. D. Schreiber, “Interfer-
ons, immunity and cancer immunoediting,” Nature Reviews
Immunology, vol. 6, no. 11, pp. 836–848, 2006.
[36] D. H. Munn, M. D. Sharma, B. Baban et al., “GCN2 kinase in
T cells mediates proliferative arrest and anergy induction in
response to indoleamine 2,3-dioxygenase,” Immunity, vol. 22,
no. 5, pp. 633–642, 2005.